Rosatom Health Technologies (RTZ) formerly Rusatom Healthcare (Rusatom Helskea)

Rosatom Health Technologies JSC (formerly Rusatom Healthcare JSC) is a division that accumulates the expertise of Rosatom State Corporation in the field of health care. The company was created on the basis of Rosatom enterprises and institutes with the aim of integrated development of medical technologies in Russia and abroad.

Rosatom Health Technologies is an integrator and management company established on the basis of enterprises and institutes of Rosatom State Corporation for the development of nuclear medicine and innovative processing technologies in Russia and abroad.

Areas of activity

Rosatom Health Technologies is developing in four main areas: comprehensive turnkey solutions for medicine; production and supply of medical isotopes and radiopharmaceuticals (supplies to 50 countries of the world); equipment for diagnostics and therapy; solutions for ionizing treatment of medical products.

2024: Renamed Rosatom Health Technologies

Rosatom has agreed with the Government of the Russian Federation to rename 21 companies that are part of the state corporation's management loop in such a way as to include the words "Russian Federation," "Russia" or their derivatives in their names. The corresponding order of the Cabinet of Ministers (of 22.01.2024 No. 109-r) was published on the official portal of legal information on January 23, 2024. According to the list approved by the order, Rusatom Healthcare JSC received the name Rosatom Health Technologies JSC (RTZ JSC).

2023

Completion of the transaction on the purchase of 100% of Akcentr shares

Rusatom Healthcare (Health Technologies Division of Rosatom State Corporation) has completed the acquisition of a 100% stake in the Accent Group of Companies, which specializes in the treatment of food and disposable medical products with ionizing radiation. On August 29, 2023, Zdrav.Expert was informed about this by representatives of the Health Technologies division of Rosatom State Corporation. Read more here.

Increase in the share in the capital of the Medskan group of companies to 50%

Rusatom Healthcare (Health Technologies division, which accumulates the expertise of Rosatom State Corporation in the field of health) bought out an additional issue of shares in Medskan JSC, increasing its stake in the capital of the group of companies to 50%. This was reported to Zdrav.Expert on July 20, 2023 by representatives of Rosatom. According to the shareholder agreement, the funds will be invested in the development of the medical holding. Read more here.

Agreement with Medtekhnocenter on the joint development of heavy-grade medical devices

On April 7, 2023, information appeared that Rusatom Healthcare JSC (medical division Rosatom"") and the Belarusian RUE Medtekhnocenter agreed on the joint implementation of a number of union programs, involving both supply Belarus to the produced in the Russian Federation and medical equipment joint development. medical devices

As Stanislav Levitsky, director of the country office of the Rosatom state corporation in Belarus, clarified, two or three union programs are planned in total. Within the framework of one of them, it is planned to develop heavy-grade medical devices (large-sized medical equipment for hospitals used for diagnostic, medical, preventive and rehabilitation purposes^[1]).

Perhaps it will be "Brachium 2.0." The ultrasound apparatus will be integrated there and the planning system will be improved. Then this equipment will completely cover the needs of the Russian Federation, Belarus and third countries, added Stanislav Levitsky.

According to the top manager, the current version of the Brahium gamma-therapeutic complex was founded by the Agat complex, which was developed in the 1980s.

The brachytherapy apparatus has not conceptually changed either in our country or abroad. The planning system, applicator technologies, and isotopes used changed. But this device is a highly modernized version of the good old device, - said Stanislav Levitsky.

The agreement signed by Rusatom Healthcare and Medtekhnocenter also consolidated the intentions of the parties on the supply of Russian medical equipment to Belarus.

As far as I know, this year it is planned to replace several devices on the territory of Belarus. We are ready to participate in the tender. If we predict the need for brachio devices for at least three to four years, then we can make a comprehensive proposal. Then the Ministry of Health can make a purchase, - added the head of the country office.

According to Stanislav Levitsky, in early April 2023, representatives of Rosatom visited two cancer centers, where they presented the Brachium apparatus.

The next development is the Onyx linear accelerator, which was registered in the Russian Federation.

As of April 2023, it is installed in several cancer centers of the Russian Federation. It is offered as an opportunity for the future because we want to present it as a finished product. When it passes the test, we will offer it too, - concluded the top manager.[2]

Creation of a joint venture "Alliance of Health Technologies"

Rusatom Healthcare JSC (a division that accumulates the expertise of Rosatom State Corporation in the field of health) and Medtech Alliance Engineering LLC, which is a supplier of a wide range of Russian and foreign medical equipment, have created a joint venture - Alliance Health Technologies LLC. Each of the parties owns a 50% stake. Representatives of Rusatom Healthcare reported this to Zdrav.Expert on April 12, 2023. Read more here.

Cooperation Agreement with FMBA of Russia for the Development of Radiopharmaceuticals

On January 19, 2023, Rusatom Healthcare JSC (a division that accumulates the expertise of Rosatom State Corporation in the field of health care) and the Federal Biomedical Agency of Russia (FMBA) signed an agreement on cooperation and interaction. Read more here.

2022

Agreement with Medtekhnocenter on the supply of medical equipment for the treatment of cancer to Belarus

On November 21, 2022, an agreement on interaction and cooperation between Rusatom Healthcare JSC and the Republican Unitary Enterprise Medtekhnocenter was signed in Sochi. The signed document fixed the intentions of the parties in relation to the organization of interaction on the supply of medical equipment produced on the territory of the Russian Federation for the treatment of oncological diseases.

The state corporation Rosatom"" has a large product portfolio in terms of the production of high-tech medical equipment. In 2022, "Rusatom Healthcare" began serial production of the first Russian linear accelerator "Onyx," as well as a complex for brachytherapy Brachium"." In addition, Rusatom Healthcare is developing a gel-free magnetic resonance tomograph (), MRI which will be more convenient to use and more reliable than analogues. Work has also begun on the creation of a domestic complex of remote radiation therapy of the toroidal type. "Thorus

Equipment of ROSATOM State Corporation of domestic development, due to which the price does not depend on the volatility of the exchange rate. Service and warranty service is provided by JSC NIITFA (an enterprise in the management loop of Rusatom Healthcare) in Moscow, which guarantees a high service speed.

We see a steady interest of the medical community in Russian high-tech equipment. And they are ready to contribute to ensuring the technological sovereignty of the Republic of Belarus in the field of the supply of healthcare equipment in order to increase the accessibility of the population to the services of high-quality high-tech medical care - said Igor Obrubov, General Director of the Rusatom Healthcare division.

The medical community of the Republic of Belarus is well acquainted with the equipment of Rosatom. For example, the predecessor of Brahium, the AGAT complex has been produced by NIITFA since 1970 and has been a great success. The signing of the agreement with Rusatom Healthcare is the first step in mutually beneficial cooperation. We are confident that in the near future, reliable and effective Russian-made equipment for the treatment and diagnosis of socially significant diseases will work in medical institutions of our country, "commented Oleg Shwed, Director of the Medical Technology Center Rosatom[3].

Purchase of 50% of the Accent network

On September 22, 2022, it became known about the sale of Aktsentr's stake in Rusatom Healthcare (a division of Rosatom that accumulates competencies in the field of health care). Financial and other terms of the transaction were not disclosed. According to TASS sources, we are talking about buying 50% of the capital of a company specializing in industrial sterilization and electron beam processing. Read more here.

Agreement with TPU for the development of innovative radiopharmaceuticals

On June 17, 2022, the Strategic Cooperation Agreement was signed between Rusatom Healthcare JSC and the federal state autonomous educational institution of the higher formations National Research Tomsk Polytechnic University "(NI TPU).

The agreement was signed by Igor Obrubov, Director General of Rusatom Healthcare JSC, and Dmitry Sednev, Acting Rector of NI TPU.

The signed document fixed the intentions of the parties in the implementation of joint activities for the development of innovative radiopharmaceutical drugs (FPM). In addition, the parties jointly plan to carry out a complex of preclinical research and marketing of the FPM.

Шаблон:Quote 'author = said Igor Obrubov, General Director of JSC "Rusatom Healthcare."

Tomsk Polytechnic University, together with its partners, implements projects aimed at creating scientific and technical foundations and technologies in the field of health and health saving, developing educational models and increasing the efficiency of translating engineering solutions into high-tech fields of medicine. Due to the fact that Rusatom Healthcare JSC is a single integrator in the field of radiation technologies for medicine and industry in the contour of Rosatom State Corporation, the agreement we signed allows in the long term to build effective and profitable interaction with the field of development, conducting a complex of preclinical research and marketing of innovative radiopharmaceutical drugs, - said Dmitry Sednev, acting rector of NI TPU.

Memorandum of Cooperation with Pharmaco Pharmaceuticals for the Development of Radiopharmaceuticals

Rusatom Healthcare, a single integrator in the field of radiation technologies for medicine industries both the contour of the State Corporation, and Rosatom the Egyptian pharmaceutical the company Pharco Pharmaceuticals agreed on the further development of cooperation and the implementation of joint projects. The companies signed the corresponding memorandum securing the intentions of the parties on June 5, 2022.

In particular, the document provides for cooperation on projects for the joint development and production of radiopharmaceuticals, preclinical, clinical studies, registration and launch of developed products on the market of the Arab Republic of Egypt, the countries of the Eurasian Economic Union and other countries.

As Igor Obrubov, General Director of Rusatom Healthcare, noted, the radiopharmaceutical industry is one of the most dynamically developing areas in medicine due to the high demand for radiopharmaceuticals by doctors and patients. Thus, radiotherapy is required for diagnosis and treatment in about 50% of patients with cancer, and about 20 million new cases are detected annually in the world. In addition, radiopharma is actively used in a number of other nosologies: cardiology, rheumatology, endocrinology. With the development of medical science, this list will expand, the head of Rusatom Healthcare is convinced.

"I am delighted that in the form of Pharmaco Pharmaceuticals, led by Dr Sheryn Helmy, we have found partners and like-minded individuals. Together, we will be able not only to establish effective production, but also to develop new drugs that doctors and patients around the world are looking forward to, "concluded Igor Obrubov.

"We highly appreciate the cooperation with Rusatom Healthcare in the field of radiopharmaceuticals. This is a new (as of 2022 - approx. Zdrav.Expert) area for Egypt has an important application in the treatment of cancer. We look forward to launching collaborative research and developing new treatment options for cancer patients, "Dr. Sherin Helmi, CEO of Pharmaco Pharmaceuticals, said in a statement.

MRI production launch plan with 1.5 Tesla magnetic field strength

The Rusatom Healthcare division, which accumulates the expertise of Rosatom State Corporation in the field of health, on April 6, 2022 announced the launch of a project to develop domestic magnetic resonance imaging devices with a magnetic field strength of 1.5 Tesla. The state corporation plans to launch mass production by 2026. The Rosatom tomograph will be the first device to meet the requirements for the origin of goods on the territory of the Russian Federation.

The implementation of the project was a timely response of ROSATOM to the growing need of Russian healthcare for domestic equipment to provide high-tech medical patient care. At the same time, MRI diagnostics are included in the list of recommended examination methods for more than thirty types of diseases, including pregnant women women for children.

Medical institutions of the Russian Federation note a high interest in domestic equipment. According to the Organization for Economic Cooperation and Development, at least 2,500 MRI devices should be installed in medical institutions of the country, and as of April 6, 2022, 1,400 are functioning.

There are no domestic analogues on the market - foreign manufacturers occupy high positions, which significantly affects the cost of equipment and the availability of MRI diagnostic services for the population.

The Rusatom Healthcare division has a serious expertise in the development of high-tech equipment for diagnostics and therapy. Thus, Scientifically the Research Institute of Technical Physics and Automation, which is part of the control circuit of Rusatom Healthcare JSC, has been producing an apparatus for contact radiation therapy (brachytherapy) since 1970. " Agate It was replaced by a new generation of devices - the gamma-therapeutic complex Brachium"," for which at the end of 2021 the institute received a registration certificate, and in 2022 the division expects to receive a registration certificate for a radiation therapy complex based on the electron accelerator Onyx"" - 6 MeV (KLT-6).

In addition, in 2021, Rusatom Healthcare and GE Healthcare signed a production agreement to localize the production of three GE magnetic resonance imaging models in Russia. Localization provides for the creation of a modern site for the production of three MRI models: Signa Creator, Signa Explorer and Signa Voyager. In 2022, the division plans to launch production under this agreement.

Rosatom State Corporation has superconducting competencies, which are one of the leading in the world - they are necessary for the development of a magnetic resonance imaging scanner in terms of the production of low-temperature superconducting products (NTSP), NTSP wires for MRI. The experience of developing a superconducting wire for MRI will allow you to successfully create a high-quality domestic product for a magnetic system.

Domestic MRI, which Rusatom Healthcare will mass-produce on the territory of the Russian Federation, belongs to the most popular segment of systems on the market with a magnetic field strength of 1.5 Tesla. The technologies that will be used in these devices will solve the largest range of problems. Low-voltage cryogenic systems that do not require refueling with helium will ensure continuity of operation and reduce cost of ownership; The wide aperture of the magnetic system tunnel will allow more patients to receive high-quality medical care. Special attention will be paid to the safety and service of the equipment.

The implementation of the project provides for the development, testing, registration of equipment at Roszdravnadzor, the launch of serial production, the creation of a center for the use of an MRI prototype for training radiologists.

{{quote 'author = said Igor Obrubov, General Director of JSC "Rusatom Healthcare." | Our task is to be a partner of the state in increasing the duration and improving the quality of life of the population. We plan to reduce the cost and time of delivery of equipment from the production site to medical institutions by centralizing the most complete range of work in a single contour of the State Corporation,}}

The production capacity of "Rusatom Healthcare" will allow the production of up to 65 MRI units annually. This will ensure a significant share of the annual demand of Russian healthcare for magnetic resonance imaging.

Appointment of Igor Obrubov as general director

On April 1, 2022, Igor Obrubov headed Rusatom Healthcare JSC, a division that accumulates the expertise of Rosatom State Corporation in the field of health care. In this post, he replaced Natalia Komarova. Read more here.

Acquisition of a 25% stake in Medskan Group of Companies

On February 16, 2022, it became known that the structure of Rosatom - JSC Rusatom Healthcare (RHK) - acquired 25.001% of Medskan Group of Companies. The owner of the medical holding Yevgeny Tugolukov told Forbes about the deal. Read more here.

2021

JV with Cosylab to develop radiotherapy software

Rusatom Healthcare JSC (a division that accumulates the expertise of Rosatom State Corporation in the field of healthcare) and the Slovenian company Cosylab, specializing in the development and implementation of digital solutions in the field of nuclear medicine, created a joint venture - RuSat Digital Healthcare LLC - and began to develop software for radiation therapy. This was announced on December 9, 2021 by representatives of Rusatom Healthcare. Read more here.

Exit from "P2med"

At the end of November 2021, it became known about the withdrawal of Rusatom Healthcare (a subsidiary of Rosatom) from a joint venture with R-Pharm - LLC |R2med. This company produces radiopharmaceuticals used to treat severe diseases. Read more here.

Plan to bring to market the Russian version of MRI GT Healthcare by the end of 2022

Localized at the Rusatom Healthcare facilities (part of the GC Rosatom""), the version of magnetic resonance imaging MRI GE Healthcare () will enter the Russian market by the end of 2022. This became known on October 7, 2021. The company began a major overhaul of the production site on the territory of the subordinate JSC "," and NIITFA GE validated the site for the assembly of MRI of the Signa line in the registration dossier. Roszdravnadzor

The total building area of ​ ​ the production and test building prepared for the release of MRI will be 930 square meters. m. This building will allow to establish the production of several dozen MRIs per year. Rusatom Healthcare plans to complete a major overhaul in December 2021 with the subsequent validation and certification of the site in order to launch production by the end of 2022.

{{quote 'Site peculiarity consists in creation of a single industrial system allowing to maintain and monitor in real time the level of liquid helium in magnetic systems. We also provide for the localization of a number of MRI production processes previously carried out by GE Healthcare plants in China and the USA. Production testing of a number of MRI elements will significantly increase the level of localization and ensure consistently high quality of products for end consumers, - said Natalya Komarova, General Director of Rusatom Healthcare. }}

Rusatom Healthcare signed an agreement with GE Healthcare to localize three 1.5 Tl high-voltage MRI models at the facilities of NIITFA JSC in June 2021.

The project intends to organize the production of three MRI models: universal Signa Creator with an aperture of 60 cm, specialized Signa Explorer and Signa Voyager with an aperture of 70 cm and a magnetic field strength of 1.5 T. The production capacity of the enterprise will allow the production of up to 50 units of MRI annually. The total investment in the project is estimated at more than $8.5 million.

In 2019 and 2020, MRI was included in the list of re-equipment of medical organizations under the Healthcare national project for cancer clinics and modernization of primary care with a total funding of 290 billion and 550 billion rubles. The Ministry of Health in January 2019 recommended purchasing domestic equipment with equivalent technical characteristics. In December 2020, the Government of the Russian Federation established a minimum quota for the purchase of domestic medical products - for MRI they amounted to 30% in 2021 with an increase to 50% in 2022 and 2023 for tenders for 223-FZ and 44-FZ^[4].

Agreement with GE Healthcare on localization of MR tomographs production in Russia

GE Healthcare and Rusatom Healthcare JSC (Rosatom State Corporation integrator in the field of radiation technologies in medicine and industry) on June 4, 2021 informed Zdrav.Expert about the creation of a local production of magnetic resonance imaging (MRI) in order to meet the growing need of the Russian population for affordable high-tech medical diagnostics.

The production agreement was signed by Elena Legezina, President and CEO of GE Healthcare in Russia/CIS, and Natalia Komarova, CEO of Rusatom Healthcare JSC in the presence of Katrin Estramp, President and CEO of GE Healthcare in EMEA (Europe, Middle East, Africa), and Kirill Komarov, First Deputy CEO - Director of the Development and International Business Unit of Rosatom State Corporation.

This is GE's first project in localizing MRI production at the site. of the Russian Federation Localization provides for the creation of a production site for three MRI models:,, Signa Creator Signa Explorer Signa Voyager. They belong to the most popular segment of systems on the market with a magnetic field strength of 1.5 Tesla. The advanced technologies used in MRI data help solve the widest range of tasks, including diagnosis oncological and cardiac diseases, and meet the clinical needs medical of institutions of all levels: from to policlinics federal scientific centers. The production capacity of the enterprise will allow the production of up to 50 units of MRI annually. This will provide a significant share of the annual need Russian healthcare for magnetic resonance imaging. The total investment in the project will exceed 8.5 million. dollars USA

"The signed agreement is a consistent step in the implementation of our strategy aimed at localizing global expertise, advanced medical technologies and innovations in. Russia We are proud that in partnership with the technological leader of the industry - the company "Rusatom Healthcare" - we participate in the modernization of the Russian system health care and contribute to increasing the availability of high-tech medical care, " - noted the president and executive director of GE Healthcare RussiaCIS in/Elena Legezina.

"Cooperation with GE Healthcare will allow us to obtain advanced technological expertise of one of the leaders in the global production of medical equipment and reduce the delivery time of high-tech equipment necessary for Russian patients from the production site to the medical institution, which is especially important for maintaining the reliability of supply chains in a pandemic. Already in 2022, the first magnetic resonance tomographs produced by Rusatom Healthcare under the agreement signed today will work in Russian clinics, "commented Natalya Komarova, General Director of Rusatom Healthcare JSC.

As noted, GE Healthcare has been localizing global expertise and technologies in Russia for more than 10 years. Since 2009, the country has launched the production of high-performance computed tomographs and ultrasound devices for general imaging, including monitoring of cancer patients, for cardiovascular and female health diagnostics.

Appointment of Natalia Komarova as CEO

The company "Rusatom Healthcare" on January 12, 2021 announced the appointment of Komarova Natalia Mikhailovna to the post of general director from January 1, 2021. Read more here.

2020

Plan for the creation of a multifunctional irradiation center at the site of the medical industrial park of Tatarstan

On December 28, 2020, information appeared that the company "Rusatom Healthcare" (part of the state corporation "Rosatom") took the initiative to create a multifunctional irradiation center for sterilization of medical devices, polymer materials and food on the site of the medical industrial park of Tatarstan. About this "Business Online" told in LLC "PharmMedPolis RT."

"Tentatively, the center will be located on a site of 1 thousand square meters. m, include a common working area and storage areas and will be fully automated. At least 10 jobs will be created, the volume of investments is being specified, "the company noted.

The advantages of this type of sterilization are a high processing speed, the possibility of packaging already finished products and ensuring the death of pathogenic forms of microorganisms in the form of spores and non-pathogenic microorganisms on the surface and inside the material.

In Tatarstan, 63% of manufacturers of medical devices in the Volga Federal District are concentrated, thus, the issue of sterilization is extremely relevant, said Albert Gayfullin, director of PharmMedPolis RT.

"Current capacities do not cope, and many manufacturers carry their products far beyond the boundaries of the district, which affects the productivity, cost and, in the end, the final cost for the customer of the manufactured products," the head said. Such a project in itself is high-cost, so it lacks an economy in the case of building a center by the manufacturer for itself. "However, in the case of contract services, it becomes profitable. And this is within the power of a large and competent player, such as "Rusatom Healthcare," "added Gayfullin.

It is expected that the project will increase the attractiveness of Tatarstan for localizing industries from all over Russia and open the next stage in the development of the healthcare industry.^[5]

Plans for the construction of 25 medical infrastructure facilities

Rosatom intends to build 25 medical infrastructure facilities within the framework of state private partnership (PPP) projects in the field health care by 2025. This became known on November 27, 2020.

The state corporation plans to open specialized centers in Siberia, the Urals and the Far East. Olga Esaulova, director of PPP development at Rusatom Healthcare, spoke about this.

According to her, the corporation plans to open three nuclear medicine centers, six radionuclide therapy departments, 11 sterilization treatment centers, three multifunctional radiation centers in the next five years, as well as create an isotope production site in Obninsk and a production site in Istra. As a result, the geography of Rosatom's presence will expand in the regions of Siberia (Yakutsk, Barnaul, Krasnoyarsk and Irkutsk), the Urals (Yekaterinburg, Ozersk and Lesnoy) and the Far East (Yuzhno-Sakhalinsk, Birobidzhan, Vladivostok).

Rosatom is interested in the development of medicine in the Russian Federation. In all regions, we would like to see our centers so that somehow we can find an approach in terms of guaranteed patient flows. This is probably the only problem, since the interaction matrix is clear within the PPP, told Olga Esaulova

Rusatom Healthcare JSC was separated from the Rosatom structure in 2017 in order to promote developments in the field of nuclear medicine to the world and domestic markets. The company implements projects in the field of radiation medicine, oncoradiology, the creation of equipment and drugs for nuclear and radiation medicine^[6]

Development of isotope business together with Rosenergoatom

On May 8, 2020, it became known that the Rosenergoatom concern, together with Rusatom Healthcare JSC and V/O Isotope JSC (part of Rosatom), began implementing a program for the development of the isotope business of the Electric Power Division of the state corporation until 2030.

According to the press service of the Civil Code, the project is designed until 2030 and provides for an increase in production volumes and an expansion of the range of production of various widely used and most popular isotopes on the world market.

Thus, the production of the So-60 isotope, used in the disinfection treatment of medical equipment, food and drinking water, is expected to double and increase the share of Rosenergoatom in the world market from 15% to 30%.

As the head of the project office for the development of the isotope business of Rosenergoatom Artur Miskov noted, at the Kursk nuclear power plant, according to the results of irradiation of the loaded cobalt absorber, about a fifth of the annual world demand for this useful isotope is formed. At the Smolensk NPP, the amount of So-60 extracted only from one power unit No. 3 is enough to sterilize 400 thousand tons of medical devices or over 2 million tons of meat.

The nomenclature for the production of medical isotopes will be expanded due to such positions as: molybdenum-99, iodine-131, iodine-125, samarium-153, lutetium-177, etc.

In addition, it is planned to develop the product direction for the doping of silicon. In the reactor plant, silicon single crystals under the influence of thermal neutrons acquire unique properties that are in demand in the military-industrial complex and the aerospace industry, where the ultra-reliability of semiconductor devices is needed.

Leniningrad NPP already in May 2020 provides about 60% of the Russian market with doped silicon.

According to Nikita Konstantinov, Deputy General Director of Rosatom State Corporation, the implementation of the basic scenario of the program will allow by 2030 to multiply the annual revenue^[7].

2019

Agreement with the Italian region of Puglia on mutual understanding in the field of nuclear medicine

On November 18, 2019, it became known that the general director of Rusatom Healthcare Alexander Shibanov, the head of the Puglia region Michele Emiliano, representatives of Moscow Sechenov University and Bari University, as well as V/O Isotope signed a memorandum of understanding in order to develop and strengthen cooperation in the field of health, therapeutic radiology in oncology and nuclear medicine in the Russian Federation and the Puglia region (Republic of Italy).

The memorandum should be the starting point of cooperation between ROSATOM and the Puglia region in the field of cooperation in such areas as R&D, nuclear medicine, professional training. The competencies accumulated by the parties, the production capabilities of ROSATOM enterprises, the active development of technologies and the modernization of the previous ones represent wide opportunities for mutually beneficial and successful cooperation in the future.

The parties discussed ways to develop cooperation and formed a plan for further steps for 2020.

Historically, Russian scientists have always had "know-how" in the field of radioisotope production. Isotope products are actively used in industry, scientific experiments and medicine. The memorandum, which we signed with Sechenov Moscow University, Bari University and Rosatom State Corporation, obviously can further contribute to the effective exchange of experience in the healthcare sector of Puglia and the Russian Federation. We hope that this agreement will also be able to bring technological innovations in the field of cancer diagnosis and therapy, noted Michele[8]

Agreement with Elekta on the localization in Russia of the production of linear accelerators for the treatment of cancer

On November 8, 2019, Rosatom announced that Rusatom Healthcare JSC had agreed to strengthen cooperation with one of the leaders in the production of medical accelerator equipment - Elekta Ltd. Read more here.

Agreement with the Nizhny Novgorod region in the field of radiation technologies

On October 10, 2019, it became known about the signing of the Memorandum of Cooperation in the Field of Radiation Technologies between Rusatom Healthcare JSC and the Ministry of Agriculture and Food Resources of the Nizhny Novgorod Region.

The document was signed by the Director General of Rusatom Healthcare JSC Alexander Shibanov and the Minister of Agriculture and Food Resources of the Nizhny Novgorod Region Nikolai Denisov. The signing ceremony took place in the presence of the first vice-governor of the region, Yevgeny Lyulin.

The memorandum provides for the approval of the basic principles of interaction between the parties in the implementation of a joint project to create industrial processing facilities for agricultural products in the Nizhny Novgorod region, which will contribute to the development of cooperation and the introduction of advanced technologies. The centers will provide phytosanitary treatment services to agricultural producers in order to reduce storage losses, kill pathogens and pathogens of food infections. The parties agreed to develop a feasibility study for the project to create a multi-purpose processing center. Alexander Shibanov stressed the importance of the signed agreement, which opens the horizons of mutually beneficial cooperation with the Nizhny Novgorod region.

{{quote 'author = said Alexander^[9] see great potential in the Nizhny Novgorod market for processing agricultural products by modern methods and are convinced of the demand for our technologies, }}

Agreement with Inversiones Gamma to establish a radiation treatment center for products and medical products in Cuba

On October 3, 2019 TAdviser , it became known that Rusatom Healthcare JSC (integrator Rosatom in the field of radiation technologies in) to medicine the Cuban Inversiones Gamma and signed To Havana an agreement on the creation of a center for radiation processing agricultural of products and sterilization in Cuba. medical devices

The multipurpose radiation center using the technology of JSC Rusatom Healthcare is planned to be built in the special economic zone of Mariel as part of a partnership with the Cuban company Inversiones Gams S. A., the documents for signing say.

The center will deal with the radiation treatment of agricultural products, which will increase its storage time and reduce the cost of electricity consumed by refrigerated plants, as well as allow to abandon the chemical treatment of fruits and vegetables. The center is also planned to be used for sterilization of medical products, pharmaceuticals, cosmetics and other products.

If the project is successfully implemented, the Parties will explore the possibility of creating a network of such Centers in Cuba^[10].

Radiopharmaceuticals

In July 2019, Rusatom Healthcare CEO Alexander Shibanov spoke about the latest developments of Rosatom for medicine. Of the most important - ​radiofarmpreparaty based on alpha emitters, alpha particle emitters. They target cancer cells without damaging the healthy. By this time, only one such drug had been registered in the world - the ​Xofigo of the German company Bayer.

Russia is leading in the world market of isotopes for medicine, while there are still very few domestic radiopharmaceuticals, Alexander Shibanov stated: we have no solvent demand in the country, the infrastructure for treatment with nuclear medicine is poorly developed, there are not enough doctors. In such conditions, it is unprofitable to develop and produce FPM. Long-term expensive clinical trials, a complex drug registration system also interfere with development.

To solve problems, doctors, developers, government officials need to coordinate efforts. You can radically change the situation in just three to four years, says the head of Rusatom Healthcare.

Cooperation with Rusat - International Network and the Institute of Nuclear Physics of the Academy of Sciences of the Republic of Uzbekistan

On April 15, 2019, it became known that Rusatom Healthcare JSC, the Rusatom International Network (RMS) industry complex and the Institute of Nuclear Physics of the Academy of Sciences of the Republic of Uzbekistan signed a memorandum of cooperation in the field of radiation technologies and nuclear medicine. Read more here.

Signing a roadmap with GE Healthcare on localization of technologies for nuclear medicine in Russia

On February 14, 2019, Rusatom Healthcare (RCK), an integrator in the field of radiation technologies in medicine and industry, and GE Healthcare signed a roadmap on the creation of local production of high-tech medical equipment in order to meet the growing need of the population of the regions of the Russian Federation for high-quality medical diagnosis and treatment of oncological diseases. The document was signed by the general director of Rusatom Healthcare JSC Alexander Shibanov and the president and chief executive officer of GE Healthcare in Russia/SNGNIN Kandelaki.

The roadmap as a whole defines the procedure for joint actions for the one and a half year period for the localization of PET/CT in Russia with the possibility of further expansion of the product line. In particular, by the end of 2020, it is planned to begin assembling computer tomographs for planning radiation therapy (CT for RT), magnetic resonance computer tomographs (MRI) and combined single-photon emission computer tomographs (SPECT/CT). The document provides for the formation of a working team, the development of a package of license agreements, terms of service and quality management programs. It also defines the timing and procedure for the design of the production site in accordance with the technical requirements, GE Healthcare quality standards, Rosatom production system and Russian regulations.

According to research, in February in Russia there are only 0.36 PET scanners per 1 million of the population, while in Europe this figure is 1.1, in Japan - 3.7, and in the USA - 7.11. According to Alexander Shibanov, for the state corporation Rosatom, the creation of production of high-tech diagnostic equipment on the territory of the Russian Federation is a question that lies not only in the plane of business, but also in the plane of social responsibility.

The purpose of this project is the participation of Rosatom State Corporation by the RCK JSC in the implementation of the Healthcare national project from 2019 to 2024 as a supplier produced in the Russian Federation of modern radiological diagnostic and radiotherapy equipment for equipping Russian medical and preventive institutions. Thus, future production will become a growth driver for the Russian medical industry, by gradually deepening the localization and development of its own production of components, - added the general director of Rusatom Healthcare.

The development and introduction of innovations in the diagnosis of oncological diseases is a key area of ​ ​ investment for GE Healthcare: for more than 10 years the company has been implementing comprehensive projects in the field of oncology in Russia and is participating in the development of nuclear medicine. According to Nina Kandelaki, President and CEO of GE Healthcare in Russia/CIS, the signed agreement is an important step for the development of the production of innovative medical equipment in the Russian Federation and will contribute to solving the most important tasks of Russian healthcare - ensuring access to high-quality medical care and reducing mortality from cancer.^[11]

Cooperation with Schwabe in the fight against oncology

On February 13, 2019, Rostec announced that Schwabe Holding and Rusatom Healthcare entered into an agreement of understanding. The parties are considering the possibility of implementing joint projects for the treatment of cancer. Read more here.

2018

Partnership with NECSA to develop nuclear medicine in South Africa

RuSat Halskea and the Nuclear Energy Corporation of South Africa (NECSA) signed an agreement on cooperation in the use of nuclear non-energy technologies on July 26, 2018. The main areas of cooperation are nuclear medicine, in particular, the diagnosis and treatment of cancer in Africa and on other continents. Read more here.

Agreement with Beta Gamma Malaysia to set up irradiation centres in Malaysia

Rusatom Halskea (an enterprise of the state corporation Rosatom) and Beta Gamma Malaysia (BGM) signed an agreement on the implementation of a project to build a network of irrigation centers in Malaysia on May 15, 2018.

The document was signed by Zulkafli Gazali, chairman of the board of directors of BGM, and Denis Cherednichenko, general director of Rusatom Helskea.

Under the terms of the agreement, the parties will develop a joint action plan for the implementation of the project for the construction of a network of irradiation centers in Malaysia. At the first stage, it is planned to build an electron beam irradiation center, which will sterilize valuable medical instruments and process fruits for export.

The irradiation center will provide Malaysia with the opportunity to create a safer and more sustainable future for all, as these technologies will change our lives. The project will promote the medical, industrial and agricultural areas of Malaysia, thus significantly improving the quality of life, "said Zulkafli Ghazali, Chairman of the Board of Directors of BGM. We highly appreciate Rosatom's assistance and hope for further development of Russian-Malaysian relations.

The signed document defines the specific stages of project development from the preparation of a feasibility study to construction and commissioning. It also stipulates that Rusatom Halskaa and BGM will prepare and sign the contract after the completion of all necessary preparatory procedures.

Taking into account the fact that Malaysia occupies a leading position in the export of disposable medical goods to foreign markets, I am sure that our cooperation will be as fruitful as possible, "said Denis Cherednichenko, General Director of RuSat Halskea.

Agreement with the CK3 on the creation of a joint venture for the sterilization of cosmetics in Brazil

The company "Rusatom Healthcare" (the management company of the state corporation "Rosatom," responsible for the development of nuclear medicine and radiation processing technology) and the Brazilian company CK3 May 15, 2018 signed an agreement to create an irradiation center in Brazil, RIA Novosti reported.

The main agreement was the project of creating a project company in the form of a joint venture, the main task of which will be the sterilization of pharmaceutical, cosmetic and medical products in Brazil using Russian technologies based on electron accelerators and X-rays.

Our joint venture represents an attractive alternative for the Brazilian market, whose solutions take into account the environmental impact. Unlike other sterilization methods, electron and X-ray accelerators do not create toxic waste, "explained CK3 CEO Rafael Giger.

We see the great potential of the Brazilian market for radiation sterilization of medical devices. The use of radiation technologies in the field of health care in Brazil significantly improves the safety and quality of the goods and services provided. With radiation treatment, large volumes of medical devices can be effectively sterilized. The products processed by this method will also increase the export potential of Brazilian companies engaged in the production of goods for medicine, "said Denis Cherednichenko, head of Rusatom Healthcare.[12]

Construction of a pharmaceutical plant in the Moscow region for 6 billion rubles.

At the end of February 2018, information appeared that Rosatom intends to invest 6 billion rubles. in the construction of a plant in the Moscow region for the production of drugs for the treatment of oncological and autoimmune diseases. The exact timing of the work is not called, however, according to market experts, the implementation of the project - from the start of construction to the release of drugs into circulation - can take at least ten years.

The Kommersant publication had at its disposal a presentation of the Agency for Technological Development (APR), which is a partner in the plant's project for the production of drugs for the treatment of oncological, autoimmune and other socially significant diseases. According to the document, its construction will be carried out by Rusatom Healthcare, a subsidiary of Rosatom.

Rusatom Healthcares confirmed that such a project is indeed being discussed, but its details are still being worked out, as a result of which they cannot be disclosed. The Asia-Pacific region declined to comment due to an agreement signed with Rosatom on non-disclosure of confidential information.

According to the deputy general director of Stada CISIVAN Glushkov, the construction of the plant may further grant Rosatom the right to conduct inspections of pharmaceutical production for their compliance with GMP standards. The corresponding draft resolution in February 2018 was developed by the Ministry of Industry and Trade. Thus, Glushkov believes, the state corporation may try to take control of some segments of the pharmaceutical industry. In turn, the products of the Rosatom plant, apparently, will be aimed at the public procurement segment.

The chances of entering this market and squeezing out the already existing players there at Rosatom are great due to a significant administrative resource, says Ivan Glushkov.[13]

Joining the Digital Health Consortium

The national consortium "Digital Health" began work in Russia, the memorandum of creation of which was signed on February 16, 2018 at the National Medical Research Center named after Almazov. The consortium is attended by the Shvabe holding (structure of Rostec Group of Companies), the Ministry of Communications and Mass Media of Russia, Rusatom Healthcare, Almazov National Medical Research Center, Lomonosov Moscow State University, ITMO University and the engineering center ElTech SPb. Read more here.

2017

Aktivs

JSC "Rusatom Healthcare" implements projects in two areas: nuclear medicine; Innovative processing technologies.

In 2017, Rusatom Healthcare JSC included:

• OJSC "V/O Isotope,"
• JSC NIITFA,
• JSC "NIFHI named after L. Ya. Karpova,"
• JSC Rusreactor,
• two centers for the production of ultrashort radionuclides based on fluorine for PET diagnostics, one of which is Nuclear Medical Technologies - Snezhinsk LLC.

He is an integrator of other enterprises of the State Corporation Rosatom"" producing products based on medical and industrial radiation technologies.

Plans for the construction of a nuclear medicine center in North Ossetia

The head of North Ossetia Vyacheslav Bitarov and the general director of Rusatom Healthcare Denis Cherednichenko during a meeting in Moscow on October 17, 2017 discussed the possibility of creating a nuclear medicine center in the republic for the diagnosis and treatment of cancer. Read more here.

Construction of a nuclear medicine center in the Far East

In September 2017, it became known about Rosatom's plans to build a nuclear medicine center in Vladivostok. The estimated investment in the project will amount to 2.5 billion rubles. Read more here.

Admission of the first patient in the center of Snezhinsk

In April 2017, the new nuclear medicine center of the Rusatom Healthcare subsidiary Nuclear Medical Technologies - Snezhinsk LLC began admitting patients for diagnosis by positron emission tomography (PET) on the basis of the Chelyabinsk oncological dispensary. Read more here.

Creation of a company with an authorized capital of 480 million rubles

In January 2017, it became known that Rosatom State Corporation will create Rusatom Healthcare (Rusatom Helskea JSC), which will promote Russian nuclear technologies for medicine and radiation technologies for radiation and sterilization centers in Russia and abroad.

The new company will become an integrator of the Russian proposal in the field of nuclear medicine technologies to bring them to world markets.

Nuclear medicine uses radioactive substances to diagnose and treat various diseases. Nuclear medicine is an actively developing area in the Russian nuclear industry aimed at developing the potential of Rosatom enterprises and creating new, non-nuclear businesses.

Sterilization of medical devices and disinfection of food products by radiation treatment is one of the applications of modern radiation technologies offered by Rosatom to its foreign partners. In particular, in 2016, an agreement was signed on the development in India with the participation of Rosatom of a network of integrated radiation sterilization centers.

As follows from the materials on the corporate information disclosure website, the authorized capital of Rusatom Healthcare will amount to 480 million, rubles 100% of the company's shares will be owned by JSC Rosatom Atomenergoprom(part of Rosatom, controls all civil assets of the Russian nuclear industry)^[14] will^[14]

Notes